SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gene therapy -- Ignore unavailable to you. Want to Upgrade?


To: Mike McFarland who wrote (2)2/6/1999 7:23:00 PM
From: Mike McFarland  Read Replies (1) | Respond to of 319
 
Some more companies,
Vical of course, forgot that one for a moment.

Here are a couple of blurbs off the last Transgene
PR too--

-- Entered into a research collaboration and licensing agreement
with Schering-Plough to develop gene therapy products based on TRANSGENE's adenoviral technology.
-- Signed an agreement with HGSI to accelerate the development
of novel gene therapy drugs. Received equity investment from
HGSI for a 10% stake in TRANSGENE.

note
techstocks.com
techstocks.com



To: Mike McFarland who wrote (2)6/17/1999 1:54:00 PM
From: Mike McFarland  Respond to of 319
 
Vascular Genetics Inc. has begun dosing patients as part of two different Phase I/II clinical trials of Vascular Endothelial Growth Factor-2 gene therapy (gtVEGF-2) in patients suffering from coronary artery disease.

biz.yahoo.com